TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -$132.91M. The highest annual figure on record is -$25.03M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$132.91M | – |
| FY2024 | Dec 31, 2024 | -$130.72M | – |
| FY2023 | Dec 31, 2023 | -$88.06M | – |
| FY2022 | Dec 31, 2022 | -$61.54M | – |
| FY2021 | Dec 31, 2021 | -$45.34M | – |
| FY2020 | Dec 31, 2020 | -$25.03M | – |
See a number that looks wrong?